Tranexamic Acid and Bupropion: The Drug Interaction Every Woman on Both Medications Needs to Understand

Why This Combination Comes Up So Often in Women's Health

Women are the primary users of both medications. Tranexamic acid is the only FDA-approved non-hormonal oral treatment for heavy menstrual bleeding (HMB), used by roughly 1 in 5 women of reproductive age who experience clinically significant blood loss each cycle. Bupropion is one of the most prescribed antidepressants in the United States, with women outnumbering men in antidepressant use at nearly every age group.

The overlap is especially common in two life-stage clusters. First, reproductive-age women with PCOS or fibroids who are prescribed tranexamic acid for heavy cycles and who also carry a diagnosis of depression or ADHD-adjacent mood disorder treated with bupropion. Second, perimenopausal women, aged roughly 45 to 55, who develop flooding periods from hormonal flux and who may already be on bupropion for perimenopausal depression or for smoking cessation. The Menopause Society notes that depressive symptoms affect up to 40 percent of women during perimenopause, making antidepressant prescribing in this window very common.

Understanding the pharmacology of each drug, and where they intersect, is not optional if you take both.

Tranexamic Acid: How It Works and Why Physicians Prescribe It to Women

Tranexamic acid is an antifibrinolytic. Its job is to slow clot breakdown. It does this by competitively blocking the lysine-binding sites on plasminogen and plasmin, preventing these proteins from attaching to fibrin and dissolving clots that are actively controlling bleeding.

FDA-Approved Uses in Women

The oral formulation Lysteda (tranexamic acid 650 mg) received FDA approval in 2009 specifically for cyclic heavy menstrual bleeding in women who do not have structural or histologic causes of HMB. The approved dose is 1,300 mg (two 650 mg tablets) taken three times daily for up to five days during menstruation.

Topical tranexamic acid (2 to 5% concentrations) is widely used off-label and in compounded formulations for melasma, a condition that disproportionately affects women, particularly during pregnancy (where it is called the mask of pregnancy) and while using hormonal contraception.

The CNS Angle: Where the Seizure Risk Enters

Here is what many women are not told: tranexamic acid, in high systemic concentrations, is a glycine-receptor antagonist in the central nervous system. Preclinical and surgical data show that intravenous tranexamic acid at doses used in cardiac and orthopedic surgery (grams per kilogram range) is associated with postoperative seizures, particularly in patients with renal impairment who cannot clear the drug efficiently. The oral doses used for HMB are far lower, but this CNS mechanism is real and matters when you add a second drug that also lowers the seizure threshold.

Topical tranexamic acid for melasma achieves very low systemic absorption. The seizure concern is largely negligible at that route of administration, though it does not disappear entirely.

Bupropion: CYP2D6 Inhibition and What That Means for Other Drugs

Bupropion (Wellbutrin, Zyban, Aplenzin) is a norepinephrine-dopamine reuptake inhibitor. It is the only antidepressant in common use that does not significantly affect serotonin, which is why it is often chosen when sexual side effects from SSRIs are a concern, or specifically prescribed off-label for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Bupropion's Two Pharmacological Hazards Relevant to This Pairing

CYP2D6 inhibition. Bupropion and its active metabolite hydroxybupropion are potent inhibitors of the CYP2D6 enzyme. This matters because CYP2D6 is responsible for metabolizing a wide array of drugs. Tranexamic acid itself is primarily renally excreted rather than hepatically metabolized via CYP2D6, which means bupropion's CYP2D6 inhibition does not directly block tranexamic acid's clearance pathway in the classic sense. The pharmacokinetic interaction here is less direct than, say, bupropion with codeine. The more clinically pressing concern is pharmacodynamic.

Seizure threshold lowering. Bupropion carries a black box warning for seizure risk. The dose-dependent seizure incidence with immediate-release bupropion at 450 mg/day is approximately 0.4 percent. Extended-release formulations at approved doses reduce this to roughly 0.1 percent. Any drug or condition that also lowers the seizure threshold adds to this risk in an additive fashion.

Why Women May Be Specifically at Higher Seizure Risk

Estrogen is proconvulsant at certain ratios relative to progesterone. Women with a history of catamenial epilepsy (seizures that cluster around menstruation, when estrogen rises relative to progesterone) are at higher baseline seizure risk. Perimenopausal hormonal volatility, with erratic estrogen surges, could theoretically increase susceptibility compared to a steady hormonal state. This is a sex-specific physiological consideration that is almost never named in standard drug-interaction resources.

The Interaction Mechanism in Plain Language

The primary concern when combining oral tranexamic acid with bupropion is pharmacodynamic additivity on seizure threshold, not a direct enzyme-pathway collision.

Here is the sequence:

1. Bupropion alone lowers the seizure threshold through its dopaminergic and noradrenergic activity, plus direct sodium-channel effects at higher concentrations.
2. Tranexamic acid in systemic circulation antagonizes glycine receptors in the CNS, an inhibitory neurotransmitter system. Blocking glycine is, by definition, excitatory. Excitatory shifts lower the seizure threshold.
3. The two drugs together produce an additive, possibly greater-than-additive, pro-excitatory CNS environment.
4. Any co-existing factor in a woman's physiology, including renal impairment (which slows tranexamic acid clearance), perimenopausal estrogen surges, sleep deprivation from night sweats, or alcohol use, adds further to this risk.

The FDA label for Lysteda specifically lists a history of seizure as a contraindication to tranexamic acid therapy. It does not list bupropion co-administration as a specific contraindication, but the mechanistic overlap is clear from first principles.

WomanRx Clinical Framework: Assessing Seizure Risk When Combining These Two Drugs

Step 1. Confirm her personal and family seizure history. Step 2. Check her current bupropion formulation and dose. XL 150 mg carries lower seizure risk than IR 300 mg taken twice daily. Step 3. Assess renal function (eGFR). Tranexamic acid dose reduction is recommended when eGFR falls below 30 mL/min/1.73 m². Step 4. Identify any additional threshold-lowering exposures: alcohol, stimulants, tramadol, antipsychotics, eating disorder history. Step 5. Consider the route of tranexamic acid. Topical carries negligible systemic exposure. If oral is needed, use the shortest effective course (up to 5 days per cycle). Step 6. Document shared decision-making in the chart.

Severity Rating and Clinical Databases

Most major drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the bupropion-tranexamic acid combination as a moderate interaction, primarily on the basis of additive seizure-threshold reduction. This is not a contraindicated pairing in the absolute sense, meaning co-prescription is permissible with appropriate clinical judgment, but the word "moderate" should not make you complacent.

A moderate interaction designation means: the combination may cause a clinically significant adverse effect in a subset of patients, particularly those with additional risk factors. Given that the adverse effect in question is a seizure, the threshold for concern should be high.

No large randomized controlled trial has directly studied this combination in women. The evidence base is built from the known pharmacodynamic profiles of each drug separately, plus case series from surgical settings where intravenous tranexamic acid was combined with CNS-active drugs. A 2012 retrospective analysis of cardiac surgery patients found that tranexamic acid dose was independently associated with postoperative seizure, with an odds ratio of 4.0 for high-dose IV exposure. Extrapolating this to oral doses is imprecise, but the mechanistic signal is consistent.

This is an area where the evidence gap is real. Women taking oral tranexamic acid for HMB are underrepresented in the seizure-risk literature, which skews heavily toward surgical populations receiving intravenous doses many times larger. Honesty about this gap is a clinical obligation.

Who This Combination Is and Is Not Right For

Women for Whom Co-Prescribing Deserves Careful Review

• Any woman with a personal history of seizure disorder, regardless of whether seizures are currently controlled. For this group, the combination is effectively contraindicated.
• Women on bupropion doses above 300 mg/day (the seizure risk climbs with dose).
• Women with chronic kidney disease (eGFR <60 mL/min/1.73 m²), because impaired renal clearance extends tranexamic acid exposure and raises CNS concentrations.
• Women with a history of eating disorders, particularly bulimia, since bupropion carries a black-box contraindication for active bulimia or anorexia due to electrolyte disturbances that further lower the seizure threshold.
• Perimenopausal women with erratic cycle patterns leading to prolonged or frequent tranexamic acid courses.

Women for Whom the Combination May Be Acceptable With Monitoring

• A woman with well-controlled depression on bupropion XL 150 mg who needs a single five-day course of tranexamic acid for a one-off heavy menstrual bleed, with no seizure history and normal renal function.
• A woman using topical tranexamic acid for melasma while on bupropion. Systemic absorption from a 2 to 5% topical preparation is low enough that the pharmacodynamic interaction is unlikely to be clinically significant, though data are limited.

Life-Stage Specific Guidance

Reproductive years (18 to 44). This is the most common prescribing scenario. If PCOS or fibroids are the underlying cause of HMB, addressing the root cause hormonally (oral contraceptives, levonorgestrel IUD) may eliminate the need for tranexamic acid entirely, removing the interaction concern. ACOG Practice Bulletin 128 supports hormonal management as a first-line option for structural HMB.

Perimenopause (roughly 45 to 55). This is the highest-risk window for this interaction because perimenopausal flooding and perimenopausal depression peak simultaneously. A levonorgestrel-releasing IUD (Mirena) is highly effective for perimenopausal HMB and would reduce or eliminate the need for recurrent tranexamic acid courses while potentially having mood-stabilizing effects via reduced anemia.

Postmenopause. Postmenopausal bleeding should never be attributed to heavy periods without investigation. Tranexamic acid is not appropriate for this group without a structural diagnosis. Bupropion prescribing in postmenopause is common for depressive episodes and sexual function; if postmenopausal bleeding is investigated and structural causes ruled out, the discussion of tranexamic acid rarely applies.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any chance you are pregnant or breastfeeding.

Tranexamic Acid in Pregnancy

Tranexamic acid crosses the placenta. Umbilical cord blood concentrations approximate maternal serum concentrations within 30 minutes of IV administration. Oral data in pregnant women is limited.

Tranexamic acid is used intravenously in obstetric hemorrhage, including postpartum hemorrhage, where the WOMAN Trial (The Lancet, 2017) demonstrated that early administration reduced death from postpartum hemorrhage by 19 percent (relative risk 0.81, 95% CI 0.65 to 1.00) when given within three hours of delivery. This is a well-established lifesaving use in the postpartum setting.

For first-trimester use for heavy menstrual-type bleeding or as a hemostatic agent in threatened miscarriage, the human data are sparse. Animal studies have not shown teratogenicity, but the absence of evidence is not evidence of absence. The FDA assigns tranexamic acid to no formal pregnancy category under current labeling, but the historical category was B based on animal data. Prescribing in the first trimester should be limited to situations where the benefit clearly outweighs the uncertain risk.

Women who use tranexamic acid cyclically for HMB should have a reliable contraception plan confirmed before each course if pregnancy is not desired, as the drug is taken at the heaviest days of the period, which are not days of peak fertility but cycle timing can be irregular.

Bupropion in Pregnancy

Bupropion carries potential risk in pregnancy. A 2010 meta-analysis found a small but statistically significant association between first-trimester bupropion exposure and cardiovascular malformations (OR 1.28, 95% CI 1.01 to 1.63), though subsequent larger studies have been mixed. The FDA label for bupropion notes that neonatal adaptation syndrome (jitteriness, feeding difficulty, respiratory distress) has been observed with third-trimester exposure.

Women of reproductive age on bupropion who are planning pregnancy should discuss the risk-benefit balance with their prescriber. Discontinuing bupropion abruptly carries its own risks, including rebound depression. This is not a simple calculation.

Lactation

Tranexamic acid is excreted into breast milk in small amounts. Available data suggest milk-to-plasma ratios are low (approximately 1 percent of the maternal dose), and short five-day oral courses for HMB are generally considered compatible with breastfeeding by LactMed. Confirm with a pharmacist or lactation consultant before use.

Bupropion is also excreted into breast milk. LactMed summarizes that infant exposure is low, but case reports exist of neonatal seizures in breastfed infants of mothers on bupropion. This is a rare event, but it is one more reason to be cautious about adding a second seizure-threshold-lowering agent (oral tranexamic acid) in a breastfeeding woman on bupropion.

Drug Interactions Beyond Bupropion: Tranexamic Acid's Broader Interaction Profile

While bupropion is the focus here, women taking tranexamic acid should know the full field of pharmacodynamic and pharmacokinetic concerns.

Other Drugs That Compound Seizure Risk With Tranexamic Acid

• Tramadol: also lowers seizure threshold; the combination with both tranexamic acid and bupropion would be high risk.
• Tricyclic antidepressants: frequently prescribed off-label for pelvic pain and endometriosis-related dysmenorrhea; additive seizure lowering.
• Antipsychotics (quetiapine, olanzapine): used in bipolar disorder, which affects women disproportionately; these also lower the seizure threshold.

Prothrombotic Drug Combinations

Tranexamic acid promotes clot stability. Combined with estrogen-containing contraceptives, which independently increase venous thromboembolism risk, there is a theoretical additive prothrombotic effect. The FDA label for Lysteda notes this interaction and advises caution, specifically recommending that combined hormonal contraceptive users discuss thromboembolism risk with their clinician. Women who carry factor V Leiden or prothrombin gene mutation are at higher risk.

Monitoring and Practical Counseling Points

If you and your prescriber decide that taking oral tranexamic acid while on bupropion is appropriate for you, here is what monitoring should look like.

Before Starting Tranexamic Acid

• Confirm no personal or first-degree-family seizure history.
• Check serum creatinine and estimate your eGFR. The FDA label recommends dose reduction to 650 mg twice daily for eGFR 30 to 60, and 650 mg once daily for eGFR <30.
• Review your bupropion formulation and dose. If you are on immediate-release bupropion at 300 mg twice daily, discuss with your prescriber whether switching to extended-release at an equivalent dose before starting tranexamic acid reduces your seizure exposure.
• Stop alcohol entirely during the five-day tranexamic acid course. Alcohol compounds bupropion-related seizure risk meaningfully.

During Each Course

• Use tranexamic acid for the minimum effective duration. Five days is the maximum labeled course length.
• Report any new headaches, visual changes, unusual muscle twitching, or episodes of confusion to your provider immediately. These may precede a seizure or indicate elevated CNS drug concentrations.
• Do not double-dose if you miss a dose. Simply take the next scheduled dose.

Patient Counseling Script (What to Tell Your Doctor Before Combining These)

Tell your prescriber: your current bupropion dose and formulation, your seizure history (personal and family), your most recent kidney function results, whether you smoke or use alcohol, and any eating disorder history. Ask specifically whether your bupropion dose can be reduced to the lowest effective level during the months you expect to need tranexamic acid, especially if your heavy periods are tied to a predictable hormonal pattern like the perimenopausal transition.

Alternatives to Consider

If the interaction risk concerns you and your clinician agrees, here are evidence-based alternatives to oral tranexamic acid for heavy menstrual bleeding that remove the seizure-risk variable entirely.

• Levonorgestrel IUD (Mirena, Liletta): reduces menstrual blood loss by up to 90 percent in women with HMB. No CNS interaction with bupropion.
• Combined oral contraceptives: effective for HMB when thromboembolism risk is acceptable; check the prothrombotic caveat above.
• Norethindrone acetate: progestin-only option effective for perimenopausal flooding, no significant interaction with bupropion.
• NSAIDs (mefenamic acid, naproxen): reduce HMB by 20 to 46 percent in controlled trials; no CNS interaction with bupropion.
• For melasma, alternatives to topical tranexamic acid include azelaic acid 20%, niacinamide serums, and strict photoprotection, all of which carry zero systemic interaction risk.

The Evidence Gap: What We Do Not Know

Women taking oral tranexamic acid for HMB at doses of 3,900 mg over five days per month have not been studied in randomized trials for seizure incidence in combination with bupropion. The signal comes from mechanistic pharmacology and surgical case series. The WOMAN Trial and the CRASH-2 trial that established IV tranexamic acid's safety profile enrolled surgical and trauma patients, not outpatient women on antidepressants.

This means the absolute risk of a seizure from taking five days of oral tranexamic acid while on bupropion XL 150 mg, in a woman with no other risk factors, is genuinely unknown. It is not zero. It is probably low. But no published study can give you a number, and any source claiming otherwise is overstating the evidence.